Search Results

GRAIL Leadership to Outline Early Cancer Detection Market Opportunity, Business Strategy, and Financial Profile MENLO PARK, Calif.--( BUSINESS WIRE )-- GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day. Members from GRAIL’s management team will outline growth drivers for Galleri ® , a clinically validated, commercially available multi-cancer early detection test, as well as the Company’s scien

Illumina, Inc. announced the successful completion of the spin-off of GRAIL. This milestone follows the company’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company.

GRAIL, Inc. announced its spin-off from Illumina is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of tomorrow, June 25, 2024.

Illumina, Inc. announced that its Board of Directors has approved the spin-off of GRAIL.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform.